Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 11 studies | 25% ± 12% | |
erythroblast | 6 studies | 59% ± 24% | |
erythrocyte | 6 studies | 61% ± 23% | |
smooth muscle cell | 5 studies | 20% ± 4% | |
endothelial cell | 5 studies | 26% ± 8% | |
epithelial cell | 5 studies | 31% ± 11% | |
connective tissue cell | 4 studies | 23% ± 7% | |
hematopoietic stem cell | 4 studies | 27% ± 11% | |
pericyte | 4 studies | 20% ± 3% | |
endothelial cell of lymphatic vessel | 4 studies | 26% ± 7% | |
mesothelial cell | 4 studies | 35% ± 18% | |
ciliated cell | 4 studies | 26% ± 7% | |
basal cell | 4 studies | 27% ± 10% | |
hematopoietic precursor cell | 3 studies | 33% ± 5% | |
classical monocyte | 3 studies | 20% ± 4% | |
conventional dendritic cell | 3 studies | 27% ± 8% | |
myofibroblast cell | 3 studies | 18% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 3866.22 | 226 / 226 | 100% | 61.49 | 406 / 406 |
ovary | 100% | 3931.97 | 180 / 180 | 100% | 40.02 | 430 / 430 |
pancreas | 100% | 1574.87 | 328 / 328 | 100% | 42.69 | 178 / 178 |
skin | 100% | 3149.78 | 1809 / 1809 | 100% | 79.47 | 472 / 472 |
thymus | 100% | 4282.96 | 653 / 653 | 100% | 78.25 | 605 / 605 |
uterus | 100% | 4015.83 | 170 / 170 | 100% | 54.61 | 459 / 459 |
brain | 100% | 3385.08 | 2641 / 2642 | 100% | 71.28 | 705 / 705 |
kidney | 100% | 3639.26 | 89 / 89 | 100% | 62.21 | 899 / 901 |
adrenal gland | 100% | 8682.22 | 258 / 258 | 100% | 64.84 | 229 / 230 |
breast | 100% | 3725.07 | 459 / 459 | 99% | 47.59 | 1112 / 1118 |
prostate | 100% | 3179.11 | 245 / 245 | 99% | 45.92 | 499 / 502 |
lung | 100% | 2694.26 | 576 / 578 | 99% | 40.58 | 1148 / 1155 |
intestine | 100% | 3381.83 | 966 / 966 | 99% | 30.16 | 521 / 527 |
bladder | 100% | 3163.52 | 21 / 21 | 99% | 44.85 | 498 / 504 |
stomach | 100% | 2494.30 | 359 / 359 | 99% | 25.82 | 282 / 286 |
esophagus | 100% | 3362.82 | 1445 / 1445 | 98% | 21.27 | 180 / 183 |
adipose | 100% | 3719.34 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 65.22 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 64.00 | 29 / 29 |
spleen | 100% | 3665.69 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 45.55 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 31.32 | 1 / 1 |
blood vessel | 100% | 3186.61 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 2568.24 | 801 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 2667.84 | 849 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 2238.88 | 916 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006787 | Biological process | porphyrin-containing compound catabolic process |
GO_0006782 | Biological process | protoporphyrinogen IX biosynthetic process |
GO_0006783 | Biological process | heme biosynthetic process |
GO_0006784 | Biological process | heme A biosynthetic process |
GO_0048034 | Biological process | heme O biosynthetic process |
GO_0006778 | Biological process | porphyrin-containing compound metabolic process |
GO_0006785 | Biological process | heme B biosynthetic process |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0004853 | Molecular function | uroporphyrinogen decarboxylase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | UROD |
Protein name | Uroporphyrinogen decarboxylase (UPD) (URO-D) (EC 4.1.1.37) Uroporphyrinogen decarboxylase (EC 4.1.1.37) Uroporphyrinogen decarboxylase |
Synonyms | |
Description | FUNCTION: Catalyzes the sequential decarboxylation of the four acetate side chains of uroporphyrinogen to form coproporphyrinogen and participates in the fifth step in the heme biosynthetic pathway . Isomer I or isomer III of uroporphyrinogen may serve as substrate, but only coproporphyrinogen III can ultimately be converted to heme . In vitro also decarboxylates pentacarboxylate porphyrinogen I . . |
Accessions | ENST00000636293.1 ENST00000652287.1 P06132 A0A494C0S8 A0A494C1T3 A0A494C1D8 A0A494BZY8 Q5T446 ENST00000486699.5 A0A494BZV1 ENST00000434478.6 ENST00000460334.5 ENST00000246337.9 ENST00000491773.6 ENST00000636836.1 A0A494C007 A0A1B0GVZ4 ENST00000652514.1 A0A1B0GVN9 Q71UD4 ENST00000469548.5 H0Y5R6 A0A494C085 ENST00000478467.5 ENST00000650713.1 Q71UD5 ENST00000428106.1 A0A494C0Q8 ENST00000652165.1 ENST00000651476.1 A0A494C0P4 |